Copyright
©The Author(s) 2024.
World J Clin Cases. Sep 6, 2024; 12(25): 5749-5760
Published online Sep 6, 2024. doi: 10.12998/wjcc.v12.i25.5749
Published online Sep 6, 2024. doi: 10.12998/wjcc.v12.i25.5749
Ref. | Study location | Number of NAFLD | Sample size (HBV+ /HBV-) | Age (year) | Gender (F/M) | Subtype of study | Diagnosis of fatty liver | Follow | Adjusted OR/RR (95%CI) |
Wang et al[20], 2008 | Taiwan | 257 | 50/457 | 44.6 ± 1.4/46.8 ± 0.4 | 264/243 | Case-control | Ultrasonography | NA | 0.97 (0.48, 1.95) |
Yun et al[21], 2009 | Korea | 44 | 68/18 | 21.0 (20-26) | 0/86 | Case-control | Liver biopsy | 2005-2006 | 1.19 (1.17, 2.83) |
Wong et al[22], 2012 | Hong Kong | 273 | 91/922 | 49 ± 10/48 ± 11 | 580/433 | Cross-sectional | MRS | 2008-2010 | 0.42 (0.20, 0.88) |
Cheng et al[23], 2013 | Taiwan | 14671 | 3642/29797 | 51.9 ± 13.1 | 15182/18257 | Cross-sectional | Ultrasonography | 2002-2009 | 0.66 (0.59, 0.72) |
Peng et al[24], 2013 | China | 527 | 253/922 | 20-74 | 438/1131 | Case-control | Ultrasonography | 2007-2008 | 3.96 (2.10, 7.48) |
Yilmaz et al[25], 2015 | Turkey | 28 | 88/0 | 31 ± 1.1 | 27/61 | Cross-sectional | Liver biopsy | NA | 0.21 (0.11, 0.41) |
Chan et al[26], 2017 | Hong Kong | 107 | 270/0 | 43.6 ± 11.3 | 67/203 | Cohort | Liver biopsy | 2006-2009 | 0.43 (0.30, 0.60) |
Joo et al[27], 2017 | Korea | 20200 | 3926/79413 | 38.5 (7.2)/ 37.5 (7.6) | 40856/42483 | Cohort | Ultrasonography | 2002-2014 | 0.78 (0.72, 0.84) |
Zhong et al[28], 2018 | China | 631 | 291/2697 | 45-66 | 1849/1139 | Case-control | Ultrasonography | 2015-2016 | 0.64 (0.42, 0.95) |
Azarkar et al[12], 2019 | Iran | 336 | 373/447 | 41.1 ± 12.9/39.8 ± 13.9 | 403/420 | Case-control | Ultrasonography | 2013-2014 | 0.62 (0.455, 0.845) |
Lee et al[29], 2019 | Korea | 70 | 321/0 | 41 (33-49) | 125/196 | Cohort | Liver biopsy | 2007-2015 | 1.56 (0.90, 2.71) |
Peleg et al[30], 2019 | Israel | 241 | 524/0 | 42.32 (18.5-83.5) | 209/315 | Cohort | Ultrasonography | 2007-2017 | 0.08 (0.02, 0.28) |
Sharif et al[31], 2019 | Pakistan | 166 | 230/0 | 36.8 ± 10.84 | 27/203 | Cross-sectional | Transient elastography | 2018-2019 | 5.4 (3.62, 8.03) |
Wang et al[13], 2019 | China | 308 | 152/1714 | 46.42 ± 10.291 | 1866/0 | Cohort | Ultrasonography | 2011-2014 | 0.656 (0.379, 1.134) |
Zhu et al[32], 2019 | China | 283 | 2393/0 | 50.7 ± 13.2 | 1767/626 | Cohort | Ultrasonography | 2012-2015 | 0.89 (0.69, 1.15) |
Huang et al[33], 2020 | China | 4917 | 2110/12342 | 43.84 ± 13.03 | 6710/7742 | Cohort | Ultrasonography | 2016-2018 | 0.717 (0.608, 0.846) |
Su et al[34], 2020 | Taiwan | 104 | 30/74 | 49.97 ± 14.76 | 47/57 | Cross-sectional | Liver biopsy | 2009-2018 | 3.55 (1.46, 8.58) |
Zhuang et al[35], 2020 | China | 88 | 46/42 | 37.37 ± 10.11/39.64 ± 12.31 | 13/75 | Cross-sectional | MRS | 2013-2016 | 0.322 (0.095, 0.550) |
Lv et al[10], 2021 | China | 6315 | 5680/10771 | 42.6 ± 11.2/46.9 ± 10.6 | 6519/9932 | Cohort | Ultrasonography | 2013-2017 | NA |
Zhou et al[36], 2022 | China | 32 | 78/105 | 45.41 ± 11.59 | 54/129 | Cross-sectional | Ultrasonography | 2019-2020 | 1.95 (0.90, 4.22) |
Ref. | Selection | Comparability | Exposure | Total score | |||||
Fully defined cases | Define the study design | Selection of controls | Described the general characteristics | Controlling the important factors or confounding factors | List inclusion and exclusion criteria for all the participants | Provided Enrollment duration for all the participants | Indicate study period and follow-up duration | ||
Wang et al[20], 2008 | * | * | * | 2 | 1 | 1 | 7 | ||
Yun et al[21], 2009 | 1 | 1 | 1 | 2 | 1 | 1 | 7 | ||
Wong et al[22], 2012 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 8 | |
Cheng et al[23], 2013 | 1 | 1 | 1 | 2 | 1 | 1 | 7 | ||
Peng et al[24], 2013 | 1 | 1 | 1 | 1 | 1 | 1 | 6 | ||
Yilmaz et al[25], 2015 | 1 | 1 | 1 | 2 | 1 | 1 | 7 | ||
Chan et al[26], 2017 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
Joo et al[27], 2017 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
Zhong et al[28], 2018 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 8 | |
Azarkar et al[12], 2019 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 8 | |
Lee et al[29], 2019 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | |
Peleg et al[30], 2019 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | |
Sharif et al[31], 2019 | 1 | 1 | 1 | 2 | 1 | 1 | 7 | ||
Wang et al[13], 2019 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
Zhu et al[32], 2019 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 8 | |
Huang et al[33], 2020 | 1 | 1 | 1 | 2 | 1 | 6 | |||
Su et al[34], 2020 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | |
Zhuang et al[35], 2020 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | |
Lv et al[10], 2021 | 1 | 1 | 1 | 2 | 1 | 1 | 7 | ||
Zhou et al[36], 2022 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 |
Heterogeneous factors | Coef. | SE | 95%CI | P value | |
Lower | Upper | ||||
Age | 0.477 | 0.391 | -0.347 | 1.302 | 0.061 |
Year | -0.020 | 0.055 | -0.136 | 0.096 | 0.723 |
Study quality | -0.527 | 0.734 | -2.075 | 1.021 | 0.718 |
Study design | -0.226 | 0.265 | -0.784 | 0.332 | 0.959 |
Diagnosis of fatty liver | -0.095 | 0.223 | -0.565 | 0.375 | 0.827 |
BMI | 0.848 | 0.389 | 0.233 | 1.673 | 0.010 |
Diabetes | 0.790 | 0.417 | -0.112 | 1.691 | 0.015 |
Study location | 0.992 | 0.082 | 0.832 | 1.182 | 0.208 |
Follow | -0.068 | 0.057 | -0.191 | 0.054 | 0.603 |
Variable | Number of studies | Random effects model | Heterogeneity | Publication bias | ||||
OR or SMD (95%CI) | P value | Q value | P value | I2 | Egger’s P value | Begg’s P value | ||
BMI (kg/m2) | 7 | OR: 1.24 (1.21, 1.27) | < 0.01 | 27.79 | < 0.01 | 78.40 | 0.69 | 0.88 |
5 | SMD: 2.40 (1.20, 3.61) | < 0.01 | 34.11 | < 0.01 | 88.30 | 0.94 | 0.73 | |
ALT | 5 | OR: 1.01 (1.00, 1.03) | 0.05 | 140.35 | < 0.01 | 97.10 | 0.38 | 0.81 |
5 | SMD: 6.76 (0.92, 12.60) | 0.02 | 24.28 | < 0.01 | 83.50 | 0.01 | 0.46 | |
Creatinine | 2 | SMD: 4.73 (4.15, 5.31) | < 0.01 | 0.17 | 0.68 | 0.00 | NA | 0.32 |
UA | 3 | SMD: 64.24 (60.75, 67.74) | < 0.01 | 0.59 | 0.74 | 0.00 | 0.16 | 0.60 |
FBG | 6 | OR: 1.58 (1.13, 1.77) | < 0.01 | 114.14 | < 0.01 | 95.60 | 0.49 | 0.85 |
5 | SMD: 1.55 (1.43, 1.68) | < 0.01 | 9.86 | 0.04 | 59.40 | 0.92 | 0.81 | |
Cholesterol | 7 | SMD: 0.37 (0.12, 0.62) | < 0.01 | 37.01 | < 0.01 | 83.80 | 0.01 | 0.76 |
LDL-C | 6 | SMD: 0.28 (0.03, 0.52) | 0.03 | 66.65 | < 0.01 | 92.50 | 0.06 | 0.71 |
Triglyceride | 6 | OR: 1.71 (1.14, 2.55) | 0.01 | 59.19 | < 0.01 | 91.60 | 0.04 | 0.45 |
HOMA-IR | 3 | OR: 1.46 (1.17, 1.83) | < 0.01 | 6.68 | 0.03 | 70.90 | 0.40 | 0.60 |
- Citation: Zhang L, Wu HD, Qian YF, Xu HY. Prevalence of nonalcoholic fatty liver disease in patients with hepatitis B: A meta-analysis. World J Clin Cases 2024; 12(25): 5749-5760
- URL: https://www.wjgnet.com/2307-8960/full/v12/i25/5749.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i25.5749